| Laura Michelle Papajcik, MS, CCC-SLP | |
|
13123 E 16th Ave, Box 030, Aurora, CO 80045-7106 | |
| (720) 777-3593 | |
| Not Available |
| Full Name | Laura Michelle Papajcik |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 13123 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497068852 | NPI | - | NPPES |
| 0001366 | Other | CO | SLP-DEPARTMENT OF REGULATORY AGENCIES DIVISION OF PROFESSIONS AND OCCUPATIONS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 242001587 (Illinois) | Primary |
| 235Z00000X | Speech-language Pathologist | 0001366 (Colorado) | Secondary |
| Provider Name | Physical Therapy & Rehabilitation Services Pc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1811541691 PECOS PAC ID: 2668723677 Enrollment ID: O20191015000106 |
News Archive
Younger colon cancer patients appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, say researchers at Georgetown Lombardi Comprehensive Cancer Center.
Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).
Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Michelle Papajcik, MS, CCC-SLP 13123 E 16th Ave, Box 030, Aurora, CO 80045-7106 Ph: (720) 777-3593 | Laura Michelle Papajcik, MS, CCC-SLP 13123 E 16th Ave, Box 030, Aurora, CO 80045-7106 Ph: (720) 777-3593 |
News Archive
Younger colon cancer patients appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, say researchers at Georgetown Lombardi Comprehensive Cancer Center.
Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).
Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.
Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).
› Verified 1 days ago
Miss Elizabeth Frances Peterson, M.A.,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2600 S Parker Rd Ste 336, Aurora, CO 80014 Phone: 303-330-3309 Fax: 303-862-9770 | |
Rebecca Aragon, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Kristina Hess, M.A., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 500 Geneva St, Aurora, CO 80010 Phone: 303-364-9311 | |
Elizabeth Marie Cuadrado, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1635 Aurora Court, 6th Floor, Ms F737, Aurora, CO 80045 Phone: 954-735-6000 | |
Cheryl Anselmo, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Box 030, Aurora, CO 80045 Phone: 720-777-6085 | |
Mrs. Melanie Lynn Wiseman, M.S. SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 2851 S Parker Rd Ste 570, Aurora, CO 80014 Phone: 303-888-4840 | |
Chloe Mizusawa, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10100 E 13th Ave, Aurora, CO 80010 Phone: 303-366-2671 |